# Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine

> **NCT00325143** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 702 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Diphtheria
- Tetanus
- Poliomyelitis
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** DTPa-HBV-IPV/Hib
- **BIOLOGICAL:** DTPa-IPV/Hib vaccine

## Key facts

- **NCT ID:** NCT00325143
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12-01
- **Primary completion:** 2007-02-01
- **Final completion:** 2007-02-01
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325143, "Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00325143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*